The FDA has granted priority review to an NDA for taletrectinib in the treatment of advanced ROS1-positive non–small cell ...
On December 20, 2024, the FDA granted accelerated approval to the combination of encorafenib (Braftovi), cetuximab (Erbitux), ...
Significant advancements in lung cancer treatment were seen throughout 2024, from new drug approvals to promising clinical ...
Priority review granted for CUTX-101 with PDUFA target action date set for June 30, 2025 Cyprium is eligible to receive ...
A first-in-class pain med and blockbusters with new indications are just a few of the possible approvals to keep an eye on in ...
Precigen submits BLA for PRGN-2012 gene therapy targeting RRP, a rare and life-threatening condition with no cure.
The website you are visiting is protected and accelerated by Incapsula. Your computer may have been infected by malware and ...
IFLScience on MSN14d
FDA Breakthrough Therapy Designation Granted For Promising Rectal Cancer DrugT he US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to a cancer drug called dostarlimab ...
A Phase 2 study showed encouraging results with Trodelvy as a second-line treatment for extensive-stage small cell lung cancer.
Mesoblast’s achievement in winning approval for its Ryoncil drug in the US in December heralds the arrival of a new class of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback